Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06053645
Other study ID # 23-003696
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 22, 2024
Est. completion date September 2025

Study information

Verified date April 2024
Source Mayo Clinic
Contact Preventive/Vascular Research Team
Phone (507) 538-7425
Email RSTCVRUPREVENT@mayo.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - BMI =30 kg/m2 - At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease - Patients evaluated in the Cardiometabolic clinic - Willingness to complete questionnaires/surveys - Ability to complete monthly self-assessments at home Exclusion Criteria: - BMI <30 kg/m2 - Pregnancy or lactating women - Hemodynamically unstable CVD - Active malignancy - Autoimmune or systemic inflammatory diseases - Severe renal or hepatic failure - Being considered unsafe to participate as determined by the study physician - Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician - Patients with active psychosis, mania, or substance use disorders

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent body weight loss Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss. 12 months
Primary Change in Body Mass Index (BMI) Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703 Baseline, 12 months
Primary Change in visceral adiposity distribution Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA). Baseline, 12 months
Secondary Change in Blood Pressure Measured in millimeters of mercury (mmHg) Baseline, 12 months
Secondary Change in point of care glucose Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing. Baseline, 12 months
Secondary Change in quality of diet Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet. Baseline, 12 months
Secondary Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D) Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress. Baseline, 12 months
Secondary Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R) Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus. Baseline, 12 months
Secondary Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress. Baseline, 12 months
Secondary Change in functional aerobic capacity (VO2 Max) VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test Baseline, 12 months
Secondary Change in artificial intelligence electrocardiogram (AI-ECG) age AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs). Baseline, 12 months
Secondary Change in E/e' E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function. Baseline, 12 months
Secondary Change in Peak Tricuspid Regurgitation (TR) Velocity Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function. Baseline, 12 months
Secondary Change in Right Atrial (RA) Pressure RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. Baseline, 12 months
Secondary Change in Left Atrial (LA) volume index LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function. Baseline, 12 months
Secondary Change in physical activity Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study. Baseline, 12 months
Secondary Change in heart rate with detection of arrhythmia Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study. Baseline, 12 months
Secondary Change in cardio fitness Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study. Baseline, 12 months
Secondary Change in six-minute walk test Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study. Baseline, 12 months
Secondary Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress. Baseline, 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2